Clinical trial · Observational
An Observational Study on Epithelioid Sarcoma
Epithelioid Sarcoma. An Observational Study
NCT03099681CI-TRIAL-00097346EPISObsrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelioid Sarcoma | Epithelioid Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Treatment for Epitheloid Sarcoma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Epitheloid Sarcoma patients
- description
- Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
- interventionNames
- Other: Treatment for Epitheloid Sarcoma
Primary outcomes (1)
- measure
- Type of treatment given to patients with ES
- timeFrame
- From diagnosis until the date of death from any cause assessed up to 60 months
- description
- Number of chemotherapy treatment received patients affected by ES
Secondary outcomes (3)
- measure
- Radiotherapy treatments
- timeFrame
- From the time of diagnosis and then every 6 months up to 60 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria 1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen 2. Signed informed consent 3. Adequate patient compliance to treatment or follow up 4. No age limit Exclusion criteria 1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. Impossibility to ensure adequate compliance
References
Publications (5)
- BACKGROUNDThway K, Jones RL, Noujaim J, Fisher C. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016 Jan;23(1):41-9. doi: 10.1097/PAP.0000000000000102. PMID 26645461
- BACKGROUNDGuillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997 Feb;21(2):130-46. doi: 10.1097/00000478-199702000-00002. PMID 9042279
- BACKGROUNDChase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985 Apr;9(4):241-63. PMID 4014539
- BACKGROUNDBos GD, Pritchard DJ, Reiman HM, Dobyns JH, Ilstrup DM, Landon GC. Epithelioid sarcoma. An analysis of fifty-one cases. J Bone Joint Surg Am. 1988 Jul;70(6):862-70. PMID 3392084
- BACKGROUNDHalling AC, Wollan PC, Pritchard DJ, Vlasak R, Nascimento AG. Epithelioid sarcoma: a clinicopathologic review of 55 cases. Mayo Clin Proc. 1996 Jul;71(7):636-42. doi: 10.1016/S0025-6196(11)63000-0. PMID 8656704